|1.||Etropolski, Mila: 16 articles (11/2015 - 06/2010)|
|2.||Rauschkolb, Christine: 14 articles (11/2015 - 05/2009)|
|3.||Okamoto, Akiko: 14 articles (08/2013 - 11/2008)|
|4.||Upmalis, David: 12 articles (08/2013 - 11/2008)|
|5.||Tzschentke, Thomas M: 11 articles (08/2014 - 10/2007)|
|6.||Steigerwald, Ilona: 10 articles (07/2015 - 01/2012)|
|7.||Lange, Bernd: 9 articles (02/2015 - 01/2010)|
|8.||Xiang, Jim: 8 articles (09/2015 - 05/2010)|
|9.||Steup, Achim: 8 articles (07/2014 - 11/2008)|
|10.||Christoph, Thomas: 8 articles (12/2013 - 10/2007)|
06/01/2015 - "This was accompanied by a significant decrease in pain-related impairments of daily activities and an improvement in quality of life with an overall good tolerability of tapentadol PR. "
01/01/2015 - "Good pain control with tapentadol PR was accompanied by markedly reduced pain-related mental and physical burden and quality of life improved. "
12/17/2012 - "This was accompanied by a significant decrease in pain-related impairments of daily activities and an improvement in quality of life (descriptive p value < or = 0.001) with an overall good tolerability of tapentadol PR. "
10/04/2012 - "This was accompanied by a significant decrease in pain-related impairments of daily activities and an improvement in quality of life (descriptive p value < or = 0.001) with an overall good tolerability of tapentadol PR. "
07/01/2009 - "Preclinical studies demonstrated that tapentadol is effective in a broad range of pain models, including nociceptive, inflammatory, visceral, mono- and polyneuropathic models. "
|2.||Low Back Pain (Lumbago)
01/01/2011 - "Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?"
08/01/2010 - "Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study."
01/01/2010 - "Approximately equivalent TDDs of tapentadol IR and tapentadol ER provided equivalent analgesic efficacy for the relief of moderate to severe chronic low back pain and were similarly well tolerated, allowing for direct conversion between the 2 formulations. "
06/01/2015 - "Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study."
08/01/2010 - "To evaluate the efficacy and safety of tapentadol extended release (ER) for the management of moderate to severe chronic low back pain. "
|3.||Neuralgia (Stump Neuralgia)
02/01/2011 - "[Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. "
05/01/2011 - "This dual mode of action may make tapentadol particularly useful in the treatment of neuropathic pain. "
01/01/2013 - "Differences in the design and duration of these phase 3 studies may limit comparisons of the efficacy results; nevertheless, this summary of efficacy results demonstrates the broad efficacy of tapentadol ER for different types of nociceptive and neuropathic pain. "
01/01/2013 - "To review the efficacy of tapentadol extended release (ER) for the management of moderate to severe chronic nociceptive and neuropathic pain. "
01/01/2011 - "In preclinical and clinical testing, tapentadol has shown efficacy against both nociceptive and neuropathic pain. "
11/01/2015 - "This study evaluated the long-term safety and tolerability of tapentadol ER in patients with chronic osteoarthritis or low back pain. "
06/01/2014 - "Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials."
06/01/2014 - "This study included patients who had completed previous tapentadol PR trials for severe low back or osteoarthritis pain. "
01/01/2012 - "Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study."
07/01/2014 - "Tapentadol prolonged release (PR) is effective and well tolerated for chronic osteoarthritis, low back, and diabetic peripheral neuropathic pain. "
01/01/2015 - "Subgroup analysis showed a higher improvement with tapentadol among patients with knee osteoarthritis and among pooled results from studies of higher quality and shorter follow-up period, although there were no statistical significant differences in the effect size between these subgroups. "
09/01/2015 - "Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain."
09/01/2015 - "Data were pooled from three similarly designed, randomized, doubleblind, placebo- and active-controlled, phase 3 studies of tapentadol ER for moderate to severe, chronic osteoarthritis knee (NCT00421928, NCT00486811) or low back (NCT00449176) pain, and data for patients ≥ 75 years of age were evaluated. "
08/01/2014 - "We performed a post hoc analysis of data pooled from three randomized, placebo- and active-controlled, phase III studies of tapentadol ER for managing chronic osteoarthritis knee (NCT00421928, NCT00486811) or low back (NCT00449176) pain (15-week, double-blind treatment period). "
06/01/2014 - "Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial."
|2.||Opioid Analgesics (Opioids)
|5.||Morphine (MS Contin)
|6.||Opioid Receptors (Opioid Receptor)
|9.||Analgesics (Analgesic Drugs)
|2.||Palliative Care (Palliative Medicine)